Pacira Bio Sciences, Inc. PCRX
We take great care to ensure that the data presented and summarized in this overview for Pacira BioSciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PCRX
View all-
Black Rock Inc. New York, NY8.01MShares$208 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$137 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$85 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$58.8 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$51.9 Million0.06% of portfolio
-
State Street Corp Boston, MA1.97MShares$51.2 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.83MShares$47.7 Million0.01% of portfolio
-
Doma Perpetual Capital Management LLC Miami, FL1.75MShares$45.5 Million16.39% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.49MShares$38.7 Million0.01% of portfolio
-
Ubs Group Ag1.37MShares$35.8 Million0.0% of portfolio
Latest Institutional Activity in PCRX
Top Purchases
Top Sells
About PCRX
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Insider Transactions at PCRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2025
|
Lauren Bullaro Riker Senior Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
30,600
+30.87%
|
-
|
|
Feb 01
2025
|
Brendan Teehan Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,000
+50.0%
|
-
|
|
Feb 01
2025
|
Frank D. Lee Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+43.84%
|
-
|
|
Feb 01
2025
|
Kristen Marie Williams Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
79,200
+30.31%
|
-
|
|
Feb 01
2025
|
Jonathan Slonin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
93,600
+33.35%
|
-
|
|
Jan 06
2025
|
Jonathan Slonin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
879
-0.93%
|
$15,822
$18.4 P/Share
|
|
Jan 02
2025
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
159
-0.42%
|
$2,862
$18.33 P/Share
|
|
Jan 02
2025
|
Jonathan Slonin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
371
-0.39%
|
$6,678
$18.33 P/Share
|
|
Jan 02
2025
|
Frank D. Lee Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,375
-8.7%
|
$168,750
$18.33 P/Share
|
|
Dec 31
2024
|
Daryl Gaugler Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
243
+0.21%
|
$3,888
$16.01 P/Share
|
|
Dec 13
2024
|
Daryl Gaugler Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
500
-0.43%
|
$9,500
$19.76 P/Share
|
|
Nov 01
2024
|
Shawn Cross Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+50.0%
|
-
|
|
Sep 13
2024
|
Daryl Gaugler Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
500
-0.43%
|
$6,000
$12.86 P/Share
|
|
Aug 16
2024
|
Laura Brege Director |
BUY
Open market or private purchase
|
Direct |
1,000
+5.39%
|
$12,000
$12.81 P/Share
|
|
Aug 16
2024
|
Marcelo Bigal Director |
BUY
Open market or private purchase
|
Direct |
1,512
+12.97%
|
$19,656
$13.25 P/Share
|
|
Aug 14
2024
|
Michael J. Yang Director |
BUY
Open market or private purchase
|
Direct |
2,000
+21.67%
|
$24,000
$12.9 P/Share
|
|
Aug 12
2024
|
Frank D. Lee Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
8,264
+7.12%
|
$99,168
$12.1 P/Share
|
|
Aug 12
2024
|
Marcelo Bigal Director |
BUY
Open market or private purchase
|
Direct |
3,400
+28.26%
|
$40,800
$12.01 P/Share
|
|
Aug 12
2024
|
Mark Froimson Director |
BUY
Open market or private purchase
|
Direct |
1,400
+8.82%
|
$15,400
$11.58 P/Share
|
|
Aug 02
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
945
-0.99%
|
$18,900
$20.05 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 927K shares |
|---|---|
| Open market or private purchase | 17.6K shares |
| Payment of exercise price or tax liability | 23.3K shares |
|---|---|
| Open market or private sale | 143K shares |